Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2007-03-09FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Risperdal Consta (risperidone) from Janssen Pharmaceuticals, Inc., marking an addition or modifi…
-
CLINICAL_TRIALS research · 2007-02-15Clinical Trial Update: Families Coping With Mental Illness Program [Phase 1]
Phase 1 clinical trial update for the Families Coping With Mental Illness program. The status of the trial is unknown and it concerns schizo…
-
FDA approval · 2007-02-09FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for HALOPERIDOL DECANOATE from Mylan Institutional LLC under the ANDA process. The approval updates …
-
CLINICAL_TRIALS trial_result · 2007-01-29Clinical Trial Update: Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety [Phase 4]
Phase 4 trial of aripiprazole for schizophrenia with co-morbid social anxiety completed.
-
CLINICAL_TRIALS trial_result · 2007-01-26Clinical Trial Update: Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder [Phase 4]
Phase 4 trial results evaluating high-dose olanzapine for schizophrenia and schizoaffective disorder have been completed, according to the u…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2007-01-05Clinical Trial Update: Association Between Schizophrenia and Cancer
This completed clinical trial studied the association between schizophrenia and cancer.
-
CLINICAL_TRIALS research · 2006-12-27Clinical Trial Update: Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia [Phase 2]
Phase 2 multicenter trial in Israel is evaluating D-Serine for schizophrenia and schizoaffective disorder. The current trial status is unkno…
-
FDA approval · 2006-12-19FDA Approved: INVEGA — Original Application (Janssen Pharmaceuticals, Inc.)
The FDA approved Janssen's INVEGA (paliperidone) under an original New Drug Application for the treatment of schizophrenia.
-
CLINICAL_TRIALS trial_result · 2006-12-08Clinical Trial Update: Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia [Phase 1]
A Phase 1 clinical trial is evaluating Reboxetine as adjuvant therapy for schizophrenia; current status is unknown.
-
FDA approval · 2006-11-29FDA Approved: ZYPREXA — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for ZYPREXA (olanzapine) submitted by Eli Lilly and Company.
-
FDA approval · 2006-11-29FDA Approved: ZYPREXA INTRAMUSCULAR — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental NDA to add an intramuscular formulation of ZYPREXA (olanzapine) from Eli Lilly and Company.
-
FDA approval · 2006-11-28FDA Approved: PERPHENAZINE — Supplemental Application (Endo USA, Inc.)
FDA approves a supplemental application for Endo USA, Inc.'s generic perphenazine product (ANDA 040226). This action updates the approval fo…
-
CLINICAL_TRIALS research · 2006-11-07Clinical Trial Update: The National Danish Schizophrenia Project
A clinical trial update for the National Danish Schizophrenia Project with Schizophrenia as the condition; status is unknown and no results …
-
FDA approval · 2006-10-31FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Clozapine from Mylan Pharmaceuticals Inc.
-
FDA approval · 2006-10-20FDA Approved: RISPERDAL CONSTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for RISPERDAL CONSTA (risperidone) from Janssen Pharmaceuticals, Inc.
-
FDA label_change · 2006-10-20FDA Approved: SEROQUEL — Supplemental Application (H2-Pharma, LLC)
FDA approved a supplemental application for SEROQUEL (quetiapine) submitted by H2-Pharma, LLC, likely involving labeling changes.
-
CLINICAL_TRIALS trial_result · 2006-10-17Clinical Trial Update: Quetiapine Decreases Smoking in Patients With Chronic Schizophrenia [NA]
A clinical trial update indicates that quetiapine reduces smoking behavior in patients with chronic schizophrenia.
-
FDA approval · 2006-10-13FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for a generic version of clozapine, manufactured by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS research · 2006-10-12Clinical Trial Update: Glucose Regulation During Risperidone and Olanzapine Treatment [NA]
A clinical trial update assessing glucose regulation during treatment with risperidone and olanzapine in schizophrenia.
-
CLINICAL_TRIALS trial_result · 2006-10-12Clinical Trial Update: Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia
This completed trial evaluated whether niacin-induced flushing can serve as a biomarker for cannabis effects on arachidonic acid pathways in…
-
CLINICAL_TRIALS research · 2006-10-11Clinical Trial Update: Cognition, Functioning and Quality of Life [Phase 4]
Phase 4 clinical trial update focusing on cognition, functioning, and quality of life in schizophrenia. The study status is completed.
-
FDA approval · 2006-10-06FDA Approved: RISPERIDONE — Supplemental Application (Janssen Pharmaceutical, Inc.)
The FDA has approved a supplemental application for Risperidone submitted by Janssen Pharmaceutical, Inc.
-
FDA approval · 2006-09-20FDA Approved: SEROQUEL — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental application for SEROQUEL (quetiapine) filed by H2-Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2006-09-11Clinical Trial Update: A Comparative Study of New Medications for Psychosis in Adolescents [NA]
This clinical trial update reports the completion of a comparative study evaluating new medications for psychosis in adolescents. The study …
-
FDA approval · 2006-08-25FDA Approved: ZYPREXA ZYDIS — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for ZYPREXA ZYDIS (olanzapine) from Eli Lilly and Company, expanding the labeling for the Zydis …